Pseudoxanthoma ElasticumCHOPXENCT07006649
CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum
A study testing Opthtalmologic diagnosis tests in people with Pseudoxanthoma Elasticum and Tomography, Optical Coherence, run by University Hospital, Angers at 1 site in France.
Trial summary
This observational study sets out to compare choriocapillaris flow deficits between healthy control subjects and patients with pseudoxanthoma elasticum. Pseudoxanthoma elasticum (PXE) is a rare, incurable hereditary disease caused by genetic mutations. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Pseudoxanthoma Elasticum, Tomography, Optical Coherence, Retinal Disease
- What is being tested?
- Opthtalmologic diagnosis tests
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- 28 Nov 2025to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participant not afflicted by the disease under investigation and without ophthalmological pathology
- Person matched in age (+/- 5 years) and gender to a case (patient with PXE in pre-atrophic stages included in the PXE cohort)
- Signature of informed consent for participation in the protocol
- Adult at time of inclusion Criteria for non-inclusion of research subjects
- Known ophthalmological diseases (maculopathy, glaucoma, optic neuropathy, retinopathy whatever the aetiology)
- Known severe myopia, defined by a sphere > - 6 dioptres
Show all 12Show fewer
- Diabetic subject
- Unable to carry out the ophthalmological examinations of the study
- Pregnant, breast-feeding or parturient woman
- Person undergoing psychiatric care under constraint
- Person subject to a legal protection measure
- Person not affiliated or not benefiting from a social security scheme
Who cannot join
- Ophthalmic pathology (maculopathy, glaucoma, optic neuropathy, retinopathy, whatever the etiology) discovered during the ophthalmic workup
- AngioOCT examination inexploitable (artifact and/or image quality less than 50/100 even after pupillary dilation)
- Severe myopia (sphere > - 6 dioptres) discovered during the ophthalmic workup.
- Case inclusion critera :
- Patient diagnosed with pseudoxanthoma elasticum, defined according to Plomp's criteria: two out of three features related to PXE: (1) two pathogenic mutations in the ABCC6 gene, and/or (2) disease-specific dermatological changes and/or (3) disease-specific ocular changes;
- Included in the PXE cohort ;
Show all 13Show fewer
- With pre-atrophic damage, i.e. at least one eye without choroidal neovessels on OCT-A, without previous intravitreal injection of anti-VEGF, and without major retinal atrophy (less than 2 papillary diameters);
- who have had an angiographic OCT (performed during follow-up consultations) with usable results (no artifacts and image quality of 50/100 or better) ;
- patient's non-objection to participation in a study
- Case criteria for non-inclusion :
- Other known ophthalmological pathology (maculopathy, glaucoma, optic neuropathy, retinopathy of any etiology)
- Severe myopia, defined by a sphere > - 6 dioptres
- Diabetic subject
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Angers University Hospital
Angers, 49000
Laurie MOUROZEAU, Doctor, +33 (0)2 41 35 32 74, Laurie.Mourozeau@chu-angers.fr
About this study
This observational study sets out to compare choriocapillaris flow deficits between healthy control subjects and patients with pseudoxanthoma elasticum. Pseudoxanthoma elasticum (PXE) is a rare, incurable hereditary disease caused by genetic mutations. The condition is characterised by excessive tissue mineralisation, which can result in a range of dermatological, vascular, and ophthalmological complications. Among these complications is the potential for visual impairment. The management of this condition is focused on the treatment of its complications. Degeneration of the retina and the choroid (the layer responsible for ensuring its vascularisation) occurs in the eye, resulting in premature degeneration. We would like to study the premature alteration of these structures, which could subsequently be used as an objective marker of the evolution of pseudoxanthoma elasticum.
Read the detailed description
CHOPXE is a single-center, cas-control, cross-sectional study with the objective of comparing choriocapillaris flow deficits by OCT angiography (OCT-A) between healthy control subjects and patients with pseudoxanthoma elasticum.
Study rationale Pseudoxanthoma elasticum (PXE) is a rare disorder, affecting between 1 in 25,000 and 1 in 100,000 people. This autosomal recessive disorder is caused by mutations in the ABCC6 gene. Mutations in the ABCC6 gene have been demonstrated to impair cellular efflux of ATP, which is ordinarily converted to inorganic pyrophosphate (PPi) and adenosine. PPi is a potent endogenous inhibitor of calcification, while adenosine contributes indirectly to calcification inhibition by suppressing the synthesis of tissue-nonspecific alkaline phosphatase (TNAP).
The disease has been shown to cause ectopic mineralization and fragmentation of tissue elastic fibres.
- The initial indications of the disease manifesting in the skin are frequently observed in childhood or adolescence. These initial signs evolve slowly and unpredictably, as evidenced by the appearance of papular skin lesions in flexural zones.
- The ophthalmological manifestations (peau d'orange, angioid striae, sub-retinal neovascularization, optic nerve drusen) may be responsible for visual impairment through central blindness.
- The presence of vascular manifestations, including peripheral arterial disease, gastrointestinal bleeding and ischaemic stroke, has been identified as a contributing factor to the premature mortality observed in patients with PXE, when compared to the general population.
Angers University Hospital is a national rare diseases reference center for PXE, with an active file of nearly 300 patients.
At present, there is no treatment available for pseudoxanthoma elasticum, with the exception of treatment for complications. A number of treatments are currently under investigation; however, there is an absence of relevant objective criteria with which to evaluate their efficacy.
The wall of the eyeball is composed of three tunics: the sclera, the choroid and the retina. The retina is composed of multiple layers, with the deepest layer being the retinal pigment epithelium (RPE). The choriocapillaris constitutes the most superficial layer of the choroid, providing blood supply to the outer retina and photoreceptors. The existence of a mutual dependence between these two structures has been established; the choriocapillaris requires the regulatory factors (vascular endothelial growth factor inhibitors) secreted by the RPE for its functionality. Conversely, the RPE is dependent on nutrients and oxygen from the systemic circulation via the choriocapillaris bloodstream to supply the photoreceptors.
Bruch's membrane is a structure located between the retinal pigment epithelium and the choriocapillaris (between the neuroretina and the systemic circulation), which regulates the exchange of molecules between these tissues. The process of pathological mineralization in pseudoxanthoma elasticum has been demonstrated to induce alterations in the exchange mechanisms between these structures, which may potentially result in the premature degradation of photoreceptors and the choriocapillaris.
Optical coherence tomography (OCT) is a widely utilised diagnostic tool in ophthalmology consultations, enabling precise analysis of retinal structures and the optic nerve. This advanced technology boasts a resolution of up to the micrometer, with no need for contact with the eye and a non-invasive procedure. This is an optical ultrasound mode, based on light interferometry. The technology utilises laser reflection from various anatomical structures to facilitate the measurement of retinal thickness. In 2014, a new imaging technology for the retinal and choroidal vascular network was developed from OCT: OCT angiography (OCT-A). The technology is based on the principle of detecting the movements of diffracting particles, such as red blood cells, in sequential OCT B-scans taken at the same point on the retina several times. This makes it possible to objectify the presence of blood vessels. The advent of this new examination has facilitated the analysis of retinal and choroidal vascularization, and in particular retinal and choroidal microcirculation in vivo, such as the choriocapillaris, on a routine clinical basis, which had previously been inaccessible.
Consequently, numerous researchers have initiated studies of the choriocapillaris, with a particular focus on the flow deficits of the choriocapillaris. This is due to the fact that the lateral resolution of OCT-A is approximately equivalent to the macular intercapillary distance, thereby precluding direct observation of the vascularization of the choriocapillaris. The choriocapillaris is responsible for relaying the systemic circulation to the outer retina, thereby providing nutrients and oxygen to the photoreceptors. Consequently, impairment to the choriocapillaris could potentially play a pivotal role in the development of numerous retinal pathologies.
A first study revealed the presence of choriocapillary flow deficits in patients exhibiting angioid streaks on the fundus, including two patients with PXE. These findings were subsequently corroborated by a subsequent study conducted on 21 patients with PXE in the pre-atrophic stages. These results, if confirmed by further studies on larger samples, could make it possible both to use choriocapillary flow deficits for the early diagnosis of PXE, as an additional diagnostic argument in atypical cases, but also to serve as an objective and relevant biomarker for interventional studies evaluating the efficacy of treatment under development.
Patient recruitment The selection of healthy control subjects is made from the database of healthy volunteers at the Clinical Research Centre (CRC) of Angers University Hospital (France), who meet the eligibility criteria. In addition, this study may also be offered to eligible persons waiting for a consultation or accompanying a relative in Angers University Hospital Ophthalmology Department.
The planned inclusion period is 1 year. PXE patients whose data will be used for matching have already been recruited as part of routine care.
It is anticipated that the study will encompass a total of 60 healthy control subjects and 60 PXE patients.
Data collected Following inclusion, participants' characteristics are collected (age, sex, general history, ophthalmological history, cardiovascular events, whether or not digestive bleeding has occurred, and whether antiaggregant or antiplatelet therapy is being taken).
The ophthalmological assessment is carried out during a scheduled consultation at the Angers University Hospital Ophthalmology Department. It includes a measurement of best corrected visual acuity, a slit lamp examination, a fundus and an OCT-A scan. These elements enable us to rule out ophthalmological pathology (maculopathy, retinopathy, optic neuropathy, glaucoma).
If the quality of the OCT-A signal is unsatisfactory (too much artifact and/or image quality signal less than 50/100), the participant is offered pupillary dilatation if there is no contraindication to dilatation (risk of closure of the iridocorneal angle). Dilatation is performed by instilling tropicamide into both eyes.
For PXE patients, additional data of interest (described below) are collected from the patient's medical file.
- ABCC6 gene mutations
- Presence or absence of disease-specific dermatological changes
- Presence or absence of disease-specific ophthalmological changes
- Presence or absence of inflammatory skin flares
- Presence or absence of arterial stenosis of the lower limbs
- Presence or absence of carotid artery dysplasia We also collect patients' age and weight, in order to calculate their body mass index and the presence of cardiovascular risk factors (diabetes, hypertension, smoking, dyslipidemia), as these factors can influence choriocapillary flow deficits, and will enable us to compare the characteristics of patients and controls.
For both PXE patients and healthy subjects, we will select a single eye for our study, choosing the eye with the least choriocapillaris flow deficits (lowest mean percentage on 6x6mm sections).
The OCT-A choriocapillaris images are exported to Image J software for image processing and calculation of the various parameters of interest (percentage of flow deficit over the entire slice and over the various subsectors).
- Being tested
- Opthtalmologic diagnosis tests
- Keywords
- comparative studies, observational study, adult, cross-sectional studies, healthy volunteers
- Medical subject headings
- Pseudoxanthoma Elasticum, Retinal Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Opthtalmologic diagnosis testsDiagnostic test
Volunteer will be tested with : measurement of visual acuity, slit-lamp examination, fundus examination, optical coherence tomography
| Study group | Role | What they receive |
|---|---|---|
| Healthy volunteers arm with opthtalmologic evaluation | Experimental | Not described Receives: Diagnostic Test: Opthtalmologic diagnosis tests |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean percentage of choriocapillary flow deficits by OCT-A on 6x6 mm scans
Comparison of macular choriocapillaris flow deficits per OCT angiography (OCT-A) between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage
Measured: Inclusion
Secondary outcomes (5)
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage : - Average percentage of choriocapillaris flow deficits per OCT-A per ETDRS grid sub-sector ;
Measured: During inclusion visit
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage : - Average percentage of choriocapillaris flow deficits per OCT-A per age, over 6x6mm ;
Measured: during inclusion visit
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage : - Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of inflammatory skin lesion in PXE patients ;
Measured: During inclusion visit
Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of arterial stenosis of the lower limbs
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage :
- Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of arterial stenosis of the lower limbs on Doppler ultrasound in PXE patients ;
Measured: During inclusion visit
Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of carotid artery dysplasia
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage :
- Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of carotid artery dysplasia on Doppler ultrasound in PXE patients ;
Measured: During inclusion visit
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Jun 2025
- Study start28 Nov 2025
- Primary completionNov 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pseudoxanthoma ElasticumStudies of the same condition, open and under way.
- More trials run by University Hospital, AngersThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University Hospital, Angers
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Laurie MOUROZEAU, Doctor, Principal investigator, University Hospital, Angers
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07006649
- Sponsor's protocol ID
- 49RC24_0254
- Other IDs
- 2025-A00674-45
- Acronym
- CHOPXE
- Status last verified
- Dec 2025
- First submitted
- 27 May 2025
- Last updated
- 8 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Contact investigator principal study and ask sponsor authorization
Study at a glance
From the registry record, last updated by the sponsor on 8 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- CHOPXE - Analysis of Choriocapillaris Flow Deficits in Patients With Pseudoxanthoma Elasticum
- ClinicalTrials.gov ID
- NCT07006649
- Acronym / sponsor ID
- CHOPXE / 49RC24_0254
- Keywords
- comparative studies, observational study, adult, cross-sectional studies, healthy volunteers
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University Hospital, AngersOther government
- Study start
- 28 Nov 2025 (actual)
- Primary completion
- Nov 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 5 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This observational study sets out to compare choriocapillaris flow deficits between healthy control subjects and patients with pseudoxanthoma elasticum. Pseudoxanthoma elasticum (PXE) is a rare, incurable hereditary disease caused by genetic mutations. The condition is characterised by excessive tissue mineralisation, which can result in a range of dermatological, vascular, and ophthalmological complications. Among these complications is the potential for visual impairment. The management of this condition is focused on the treatment of its complications. Degeneration of the retina and the choroid (the layer responsible for ensuring its vascularisation) occurs in the eye, resulting in premature degeneration. We would like to study the premature alteration of these structures, which could subsequently be used as an objective marker of the evolution of pseudoxanthoma elasticum.
Detailed description
CHOPXE is a single-center, cas-control, cross-sectional study with the objective of comparing choriocapillaris flow deficits by OCT angiography (OCT-A) between healthy control subjects and patients with pseudoxanthoma elasticum.
Study rationale Pseudoxanthoma elasticum (PXE) is a rare disorder, affecting between 1 in 25,000 and 1 in 100,000 people. This autosomal recessive disorder is caused by mutations in the ABCC6 gene. Mutations in the ABCC6 gene have been demonstrated to impair cellular efflux of ATP, which is ordinarily converted to inorganic pyrophosphate (PPi) and adenosine. PPi is a potent endogenous inhibitor of calcification, while adenosine contributes indirectly to calcification inhibition by suppressing the synthesis of tissue-nonspecific alkaline phosphatase (TNAP).
The disease has been shown to cause ectopic mineralization and fragmentation of tissue elastic fibres.
- The initial indications of the disease manifesting in the skin are frequently observed in childhood or adolescence. These initial signs evolve slowly and unpredictably, as evidenced by the appearance of papular skin lesions in flexural zones.
- The ophthalmological manifestations (peau d'orange, angioid striae, sub-retinal neovascularization, optic nerve drusen) may be responsible for visual impairment through central blindness.
- The presence of vascular manifestations, including peripheral arterial disease, gastrointestinal bleeding and ischaemic stroke, has been identified as a contributing factor to the premature mortality observed in patients with PXE, when compared to the general population.
Angers University Hospital is a national rare diseases reference center for PXE, with an active file of nearly 300 patients.
At present, there is no treatment available for pseudoxanthoma elasticum, with the exception of treatment for complications. A number of treatments are currently under investigation; however, there is an absence of relevant objective criteria with which to evaluate their efficacy.
The wall of the eyeball is composed of three tunics: the sclera, the choroid and the retina. The retina is composed of multiple layers, with the deepest layer being the retinal pigment epithelium (RPE). The choriocapillaris constitutes the most superficial layer of the choroid, providing blood supply to the outer retina and photoreceptors. The existence of a mutual dependence between these two structures has been established; the choriocapillaris requires the regulatory factors (vascular endothelial growth factor inhibitors) secreted by the RPE for its functionality. Conversely, the RPE is dependent on nutrients and oxygen from the systemic circulation via the choriocapillaris bloodstream to supply the photoreceptors.
Bruch's membrane is a structure located between the retinal pigment epithelium and the choriocapillaris (between the neuroretina and the systemic circulation), which regulates the exchange of molecules between these tissues. The process of pathological mineralization in pseudoxanthoma elasticum has been demonstrated to induce alterations in the exchange mechanisms between these structures, which may potentially result in the premature degradation of photoreceptors and the choriocapillaris.
Optical coherence tomography (OCT) is a widely utilised diagnostic tool in ophthalmology consultations, enabling precise analysis of retinal structures and the optic nerve. This advanced technology boasts a resolution of up to the micrometer, with no need for contact with the eye and a non-invasive procedure. This is an optical ultrasound mode, based on light interferometry. The technology utilises laser reflection from various anatomical structures to facilitate the measurement of retinal thickness. In 2014, a new imaging technology for the retinal and choroidal vascular network was developed from OCT: OCT angiography (OCT-A). The technology is based on the principle of detecting the movements of diffracting particles, such as red blood cells, in sequential OCT B-scans taken at the same point on the retina several times. This makes it possible to objectify the presence of blood vessels. The advent of this new examination has facilitated the analysis of retinal and choroidal vascularization, and in particular retinal and choroidal microcirculation in vivo, such as the choriocapillaris, on a routine clinical basis, which had previously been inaccessible.
Consequently, numerous researchers have initiated studies of the choriocapillaris, with a particular focus on the flow deficits of the choriocapillaris. This is due to the fact that the lateral resolution of OCT-A is approximately equivalent to the macular intercapillary distance, thereby precluding direct observation of the vascularization of the choriocapillaris. The choriocapillaris is responsible for relaying the systemic circulation to the outer retina, thereby providing nutrients and oxygen to the photoreceptors. Consequently, impairment to the choriocapillaris could potentially play a pivotal role in the development of numerous retinal pathologies.
A first study revealed the presence of choriocapillary flow deficits in patients exhibiting angioid streaks on the fundus, including two patients with PXE. These findings were subsequently corroborated by a subsequent study conducted on 21 patients with PXE in the pre-atrophic stages. These results, if confirmed by further studies on larger samples, could make it possible both to use choriocapillary flow deficits for the early diagnosis of PXE, as an additional diagnostic argument in atypical cases, but also to serve as an objective and relevant biomarker for interventional studies evaluating the efficacy of treatment under development.
Patient recruitment The selection of healthy control subjects is made from the database of healthy volunteers at the Clinical Research Centre (CRC) of Angers University Hospital (France), who meet the eligibility criteria. In addition, this study may also be offered to eligible persons waiting for a consultation or accompanying a relative in Angers University Hospital Ophthalmology Department.
The planned inclusion period is 1 year. PXE patients whose data will be used for matching have already been recruited as part of routine care.
It is anticipated that the study will encompass a total of 60 healthy control subjects and 60 PXE patients.
Data collected Following inclusion, participants' characteristics are collected (age, sex, general history, ophthalmological history, cardiovascular events, whether or not digestive bleeding has occurred, and whether antiaggregant or antiplatelet therapy is being taken).
The ophthalmological assessment is carried out during a scheduled consultation at the Angers University Hospital Ophthalmology Department. It includes a measurement of best corrected visual acuity, a slit lamp examination, a fundus and an OCT-A scan. These elements enable us to rule out ophthalmological pathology (maculopathy, retinopathy, optic neuropathy, glaucoma).
If the quality of the OCT-A signal is unsatisfactory (too much artifact and/or image quality signal less than 50/100), the participant is offered pupillary dilatation if there is no contraindication to dilatation (risk of closure of the iridocorneal angle). Dilatation is performed by instilling tropicamide into both eyes.
For PXE patients, additional data of interest (described below) are collected from the patient's medical file.
- ABCC6 gene mutations
- Presence or absence of disease-specific dermatological changes
- Presence or absence of disease-specific ophthalmological changes
- Presence or absence of inflammatory skin flares
- Presence or absence of arterial stenosis of the lower limbs
- Presence or absence of carotid artery dysplasia We also collect patients' age and weight, in order to calculate their body mass index and the presence of cardiovascular risk factors (diabetes, hypertension, smoking, dyslipidemia), as these factors can influence choriocapillary flow deficits, and will enable us to compare the characteristics of patients and controls.
For both PXE patients and healthy subjects, we will select a single eye for our study, choosing the eye with the least choriocapillaris flow deficits (lowest mean percentage on 6x6mm sections).
The OCT-A choriocapillaris images are exported to Image J software for image processing and calculation of the various parameters of interest (percentage of flow deficit over the entire slice and over the various subsectors).
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Healthy volunteers arm with opthtalmologic evaluation | Experimental | Diagnostic Test: Opthtalmologic diagnosis tests |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (12 listed)
- Participant not afflicted by the disease under investigation and without ophthalmological pathology
- Person matched in age (+/- 5 years) and gender to a case (patient with PXE in pre-atrophic stages included in the PXE cohort)
- Signature of informed consent for participation in the protocol
- Adult at time of inclusion Criteria for non-inclusion of research subjects
- Known ophthalmological diseases (maculopathy, glaucoma, optic neuropathy, retinopathy whatever the aetiology)
Key exclusion criteria (13 listed)
- Ophthalmic pathology (maculopathy, glaucoma, optic neuropathy, retinopathy, whatever the etiology) discovered during the ophthalmic workup
- AngioOCT examination inexploitable (artifact and/or image quality less than 50/100 even after pupillary dilation)
- Severe myopia (sphere > - 6 dioptres) discovered during the ophthalmic workup.
- Patient diagnosed with pseudoxanthoma elasticum, defined according to Plomp's criteria: two out of three features related to PXE: (1) two pathogenic mutations in the ABCC6 gene, and/or (2) disease-specific dermatological changes and/or (3) disease-specific ocular changes;
- Included in the PXE cohort ;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Opthtalmologic diagnosis testsVolunteer will be tested with : measurement of visual acuity, slit-lamp examination, fundus examination, optical coherence tomography | Diagnostic test | Healthy volunteers arm with opthtalmologic evaluation |
Primary outcome
Mean percentage of choriocapillary flow deficits by OCT-A on 6x6 mm scans
Time frame: Inclusion
Comparison of macular choriocapillaris flow deficits per OCT angiography (OCT-A) between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage
5 secondary outcomes
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage : - Average percentage of choriocapillaris flow deficits per OCT-A per ETDRS grid sub-sector ;
Time frame: During inclusion visit
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage : - Average percentage of choriocapillaris flow deficits per OCT-A per age, over 6x6mm ;
Time frame: during inclusion visit
comparison between healthy controls and patients with pseudoxanthoma elasticum in pre-atrophic stage : - Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of inflammatory skin lesion in PXE patients ;
Time frame: During inclusion visit
Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of arterial stenosis of the lower limbs
Time frame: During inclusion visit
Average percentage of choriocapillaris flow deficits per OCT-A according to the presence of carotid artery dysplasia
Time frame: During inclusion visit
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Dec 2025.
- Individual participant dataSharing planned: Yes. Contact investigator principal study and ask sponsor authorization
Related trials for Pseudoxanthoma Elasticum
Recruiting
Purinergic Compounds in Pseudoxanthoma Elasticum
Pseudoxanthoma Elasticum
RecruitingObservational study
Impact of Optimized Recruitment and Follow-up of Patients With Pseudoxanthoma Elasticum (PXE)
Pseudoxanthoma Elasticum
RecruitingObservational study
Progression Assessment of PXE-associated Alterations
Pseudoxanthoma Elasticum, Angioid Streaks
Active, not recruitingObservational study
Progression Rate of Pseudoxanthoma Elasticum-associated Choroidal and Retinal Degeneration
Pseudoxanthoma Elasticum
Recruiting
PPI Supplementation to Fight ECtopIc Calcification in PXE
Pseudoxanthoma Elasticum
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Laurie MOUROZEAU, Doctor principal investigator
University Hospital, Angers
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Opthtalmologic diagnosis tests in people with Pseudoxanthoma Elasticum and Tomography, Optical Coherence, run by University Hospital, Angers at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 8 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Laurie MOUROZEAU, Doctor (+33 (0)2 41 35 32 74, Laurie.Mourozeau@chu-angers.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean percentage of choriocapillary flow deficits by OCT-A on 6x6 mm scans (time frame: Inclusion). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Dec 2025.